Sean Scanlan - Mar 2, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role: SVP, Marketing
Signature: /s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Stock symbol: TMCI
Transactions as of: Mar 2, 2022
Transactions value $: -$494,300
Form type: 4
Date filed: 3/4/2022, 04:23 PM
Previous filing: Feb 10, 2022
Next filing: Mar 10, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TMCI	Common Stock	Options Exercise	$26.3K	+25K		$1.05^*	25K	Mar 2, 2022	Direct	F1
transaction	TMCI	Common Stock	Sale	-$521K	-25K	-100%	$20.82	0	Mar 2, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TMCI	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-16.76%	$0.00	124K	Mar 2, 2022	Common Stock	25K	$1.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.